The bill now awaits President Trump's ature. How much will you get — and when?
Funny group chat names to make you laugh like your friends do
The election is settled, Congress will be split so narrowly that major legislative initiatives are unlikely, and the long-awaited COVID vaccines chaf starting to enter circulation. In short, we have a combination of risk and reward setting up, for investors willing to put some skin in the game.
And for those who are truly ready to shoulder the extra risk, A lunch day off friend stocks can be the chag choice for a major rally. But some penny stocks are fundamentally sound, and with their low price already baked in, they have nowhere to go but up. Palatin Technologies PTN We'll start with Palatin Technologies, a biopharmaceutical company with a unique niche and a competitive advantage.
Palatin specializes in the development of melanocortin and natriuretic peptide receptor systems. These are a new grroup of potential medications, receptor-specific and highly targeted toward specific diseases. Palatin has drugs in development for dry eye disease, obesity, and congestive heart failure.
For the competitive advantage, Palatin has Vyleesi. Vyleesi is the marketing brand name of bremelanotide, the first melanocortin peptide treatment for premenopausal women with generalized hypoactive sexual desire disorder. Palatin has been marketing Vyleesi in North America since then.
We believe a new re-licensing agreement could carry a meaningful upfront payment, given that Vyleesi has full FDA approval," the 5-star analyst opined. Newman points out that the "showed statistically ificant improvement in multiple s and symptoms in the moderate to severe Sacramento girls naked population.
Mustang has a robust research pipeline, with gene therapies, hematologic CAR-Ts, and solid tumor CAR-Ts in development to treat a wide range of diseases. Pre-clinical research is ongoing, and Phase 1 and 2 trials are planned through The company has six z trials ongoing, for conditions ranging from glioblastomas to multiple myeloma to prostate cancer.
In his detailed review of the company for B. Riley Securities, analyst Justin Zelin notes the early success of MB, and its potential for the company going forward. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. namea
The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.